tiprankstipranks
CSPC Pharmaceutical Group Limited (HK:1093)
:1093
Hong Kong Market
1093
CSPC Pharmaceutical Group
RESEARCH TOOLSreports

CSPC Pharmaceutical Group (1093) Stock Forecast & Price Target

31 Followers
See the Price Targets and Ratings of:

1093 Analyst Ratings

Moderate Buy
12Ratings
Moderate Buy
6 Buy
4 Hold
2 Sell
Based on 12 analysts giving stock ratings to
CSPC
Pharmaceutical Group
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1093 Stock 12 Month Forecast

Average Price Target

HK$11.28
▲(21.80% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for CSPC Pharmaceutical Group in the last 3 months. The average price target is HK$11.28 with a high forecast of HK$19.25 and a low forecast of HK$7.20. The average price target represents a 21.80% change from the last price of HK$9.26.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"HK$3","20":"HK$20","7.25":"HK$7.25","11.5":"HK$11.5","15.75":"HK$15.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19.250000011346334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$19.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.2783721616,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$11.28</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.200000004243824,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$7.20</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,7.25,11.5,15.75,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.58,10.323846154718948,11.067692309437899,11.811538464156847,12.555384618875795,13.299230773594743,14.043076928313692,14.786923083032642,15.53076923775159,16.274615392470537,17.01846154718949,17.762307701908437,18.506153856627385,{"y":19.250000011346334,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.58,9.71064401243077,9.841288024861539,9.971932037292309,10.102576049723076,10.233220062153846,10.363864074584615,10.494508087015385,10.625152099446154,10.755796111876924,10.886440124307693,11.017084136738461,11.14772814916923,{"y":11.2783721616,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.58,9.396923077249525,9.21384615449905,9.030769231748575,8.8476923089981,8.664615386247625,8.481538463497149,8.298461540746676,8.115384617996199,7.932307695245724,7.749230772495249,7.566153849744774,7.383076926994299,{"y":7.200000004243824,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.579,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.328,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.496,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.583,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.74,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.824,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.228,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.65,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.43,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.15,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 46, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.58,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$19.25Average Price TargetHK$11.28Lowest Price TargetHK$7.20
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
CMB International Securities Analyst forecast on HK:1093
Jill Wu
CMB International Securities
CMB International Securities
HK$13.93→HK$13.05
Buy
40.93%
Upside
Reiterated
03/26/26
Analysts Offer Insights on Healthcare Companies: Vyome Holdings (NASDAQ: HIND) and CSPC Pharmaceutical Group (Other OTC: CHJTF)
UOB Kay Hian Analyst forecast on HK:1093
Unknown Analyst
UOB Kay Hian
Not Ranked
UOB Kay Hian
HK$8.8
Hold
-4.97%
Downside
Upgraded
03/26/26
UOB Kay Hian upgrades CSPC Pharmaceutical Group (CHJTF) to a Hold
Bank of China Analyst forecast on HK:1093
Unknown Analyst
Bank of China
Not Ranked
Bank of China
HK$9.1
Hold
-1.73%
Downside
Upgraded
03/26/26
CSPC Pharmaceutical Group (CHJTF) was upgraded to a Hold Rating at Bank of China
Bank of America Securities Analyst forecast on HK:1093
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
HK$8
Sell
-13.61%
Downside
Reiterated
03/26/26
Bank of America Securities Remains a Sell on CSPC Pharmaceutical Group (CHJTF)
CICC Analyst forecast on HK:1093
Unknown Analyst
CICC
Not Ranked
CICC
HK$12
Buy
29.59%
Upside
Reiterated
03/26/26
CICC Remains a Buy on CSPC Pharmaceutical Group (CHJTF)
Jefferies Analyst forecast on HK:1093
Chu Wang
Jefferies
Jefferies
HK$7.2
Sell
-22.25%
Downside
Reiterated
03/25/26
Jefferies Sticks to Their Sell Rating for CSPC Pharmaceutical Group (CHJTF)
Citi Analyst forecast on HK:1093
John Yung
Citi
Citi
HK$12.1→HK$11.5
Buy
24.19%
Upside
Reiterated
03/25/26
Analysts Are Bullish on These Healthcare Stocks: Cardiff Oncology (CRDF), CSPC Pharmaceutical Group (CHJTF)
UBS Analyst forecast on HK:1093
Anita Wei
UBS
UBS
HK$10.9
Hold
17.71%
Upside
Reiterated
03/25/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: vTv Therapeutics (NASDAQ: VTVT) and CSPC Pharmaceutical Group (Other OTC: CHJTF)
Guotai Haitong Analyst forecast on HK:1093
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
HK$16.58→HK$13.19
Buy
42.44%
Upside
Reiterated
03/25/26
CSPC Pharmaceutical Group (CHJTF) Receives a Buy from Guotai Haitong
Bernstein Analyst forecast on HK:1093
Rebecca Liang
Bernstein
Bernstein
HK$10.7
Hold
15.55%
Upside
Reiterated
02/09/26
Bernstein Sticks to Their Hold Rating for CSPC Pharmaceutical Group (CHJTF)
Huatai Securities Analyst forecast on HK:1093
Unknown Analyst
Huatai Securities
Not Ranked
Huatai Securities
HK$12.75→HK$19.25
Buy
107.88%
Upside
Reiterated
02/02/26
Huatai Securities Reaffirms Their Buy Rating on CSPC Pharmaceutical Group (CHJTF)
Goldman Sachs Analyst forecast on HK:1093
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
HK$10.57→HK$11.87
Buy
28.19%
Upside
Reiterated
02/02/26
Goldman Sachs Reaffirms Their Buy Rating on CSPC Pharmaceutical Group (CHJTF)
Guoyuan Securities (HK) Analyst forecast on HK:1093
Unknown Analyst
Guoyuan Securities (HK)
Not Ranked
Guoyuan Securities (HK)
HK$10.11
Buy
9.18%
Upside
Reiterated
12/10/25
CSPC Pharmaceutical Group (CHJTF) Gets a Buy from Guoyuan Securities (HK)
First Shanghai Securities Analyst forecast on HK:1093
Unknown Analyst
First Shanghai Securities
Not Ranked
First Shanghai Securities
HK$10.03
Buy
8.32%
Upside
Reiterated
12/08/25
CSPC Pharmaceutical Group (CHJTF) Receives a Buy from First Shanghai Securities
Macquarie Analyst forecast on HK:1093
Tony Ren
Macquarie
Macquarie
HK$12.9→HK$12.4
Buy
33.91%
Upside
Reiterated
11/25/25
Analysts Are Bullish on These Healthcare Stocks: Sanofi (SNYNF), CSPC Pharmaceutical Group (CHJTF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
CMB International Securities Analyst forecast on HK:1093
Jill Wu
CMB International Securities
CMB International Securities
HK$13.93→HK$13.05
Buy
40.93%
Upside
Reiterated
03/26/26
Analysts Offer Insights on Healthcare Companies: Vyome Holdings (NASDAQ: HIND) and CSPC Pharmaceutical Group (Other OTC: CHJTF)
UOB Kay Hian Analyst forecast on HK:1093
Unknown Analyst
UOB Kay Hian
Not Ranked
UOB Kay Hian
HK$8.8
Hold
-4.97%
Downside
Upgraded
03/26/26
UOB Kay Hian upgrades CSPC Pharmaceutical Group (CHJTF) to a Hold
Bank of China Analyst forecast on HK:1093
Unknown Analyst
Bank of China
Not Ranked
Bank of China
HK$9.1
Hold
-1.73%
Downside
Upgraded
03/26/26
CSPC Pharmaceutical Group (CHJTF) was upgraded to a Hold Rating at Bank of China
Bank of America Securities Analyst forecast on HK:1093
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
HK$8
Sell
-13.61%
Downside
Reiterated
03/26/26
Bank of America Securities Remains a Sell on CSPC Pharmaceutical Group (CHJTF)
CICC Analyst forecast on HK:1093
Unknown Analyst
CICC
Not Ranked
CICC
HK$12
Buy
29.59%
Upside
Reiterated
03/26/26
CICC Remains a Buy on CSPC Pharmaceutical Group (CHJTF)
Jefferies Analyst forecast on HK:1093
Chu Wang
Jefferies
Jefferies
HK$7.2
Sell
-22.25%
Downside
Reiterated
03/25/26
Jefferies Sticks to Their Sell Rating for CSPC Pharmaceutical Group (CHJTF)
Citi Analyst forecast on HK:1093
John Yung
Citi
Citi
HK$12.1→HK$11.5
Buy
24.19%
Upside
Reiterated
03/25/26
Analysts Are Bullish on These Healthcare Stocks: Cardiff Oncology (CRDF), CSPC Pharmaceutical Group (CHJTF)
UBS Analyst forecast on HK:1093
Anita Wei
UBS
UBS
HK$10.9
Hold
17.71%
Upside
Reiterated
03/25/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: vTv Therapeutics (NASDAQ: VTVT) and CSPC Pharmaceutical Group (Other OTC: CHJTF)
Guotai Haitong Analyst forecast on HK:1093
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
HK$16.58→HK$13.19
Buy
42.44%
Upside
Reiterated
03/25/26
CSPC Pharmaceutical Group (CHJTF) Receives a Buy from Guotai Haitong
Bernstein Analyst forecast on HK:1093
Rebecca Liang
Bernstein
Bernstein
HK$10.7
Hold
15.55%
Upside
Reiterated
02/09/26
Bernstein Sticks to Their Hold Rating for CSPC Pharmaceutical Group (CHJTF)
Huatai Securities Analyst forecast on HK:1093
Unknown Analyst
Huatai Securities
Not Ranked
Huatai Securities
HK$12.75→HK$19.25
Buy
107.88%
Upside
Reiterated
02/02/26
Huatai Securities Reaffirms Their Buy Rating on CSPC Pharmaceutical Group (CHJTF)
Goldman Sachs Analyst forecast on HK:1093
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
HK$10.57→HK$11.87
Buy
28.19%
Upside
Reiterated
02/02/26
Goldman Sachs Reaffirms Their Buy Rating on CSPC Pharmaceutical Group (CHJTF)
Guoyuan Securities (HK) Analyst forecast on HK:1093
Unknown Analyst
Guoyuan Securities (HK)
Not Ranked
Guoyuan Securities (HK)
HK$10.11
Buy
9.18%
Upside
Reiterated
12/10/25
CSPC Pharmaceutical Group (CHJTF) Gets a Buy from Guoyuan Securities (HK)
First Shanghai Securities Analyst forecast on HK:1093
Unknown Analyst
First Shanghai Securities
Not Ranked
First Shanghai Securities
HK$10.03
Buy
8.32%
Upside
Reiterated
12/08/25
CSPC Pharmaceutical Group (CHJTF) Receives a Buy from First Shanghai Securities
Macquarie Analyst forecast on HK:1093
Tony Ren
Macquarie
Macquarie
HK$12.9→HK$12.4
Buy
33.91%
Upside
Reiterated
11/25/25
Analysts Are Bullish on These Healthcare Stocks: Sanofi (SNYNF), CSPC Pharmaceutical Group (CHJTF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CSPC Pharmaceutical Group

3 Months
xxx
Success Rate
8/14 ratings generated profit
57%
Average Return
+11.36%
reiterated a xxx
 rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +11.36% per trade.
1 Year
Yolanda HuMorgan Stanley
Success Rate
2/3 ratings generated profit
67%
Average Return
+12.20%
reiterated a buy rating 8 months ago
Copying Yolanda Hu's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +12.20% per trade.
2 Years
xxx
Success Rate
16/20 ratings generated profit
80%
Average Return
+26.20%
reiterated a xxx
 rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +26.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1093 Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
14
12
16
14
16
Buy
0
0
0
0
0
Hold
15
14
45
46
49
Sell
4
4
3
0
2
Strong Sell
0
0
0
0
0
total
33
30
64
60
67
In the current month, 1093 has received 16 Buy Ratings, 49 Hold Ratings, and 2 Sell Ratings. 1093 average Analyst price target in the past 3 months is 11.28.
Each month's total comprises the sum of three months' worth of ratings.

1093 Financial Forecast

1093 Earnings Forecast

Next quarter’s earnings estimate for 1093 is HK$0.10 with a range of HK$0.10 to HK$0.10. The previous quarter’s EPS was HK$0.04. 1093 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 1093 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1093 is HK$0.10 with a range of HK$0.10 to HK$0.10. The previous quarter’s EPS was HK$0.04. 1093 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 1093 has Performed in-line its overall industry.

1093 Sales Forecast

Next quarter’s sales forecast for 1093 is HK$8.01B with a range of HK$7.16B to HK$8.85B. The previous quarter’s sales results were HK$13.94B. 1093 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 1093 has Performed in-line its overall industry.
Next quarter’s sales forecast for 1093 is HK$8.01B with a range of HK$7.16B to HK$8.85B. The previous quarter’s sales results were HK$13.94B. 1093 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 1093 has Performed in-line its overall industry.

1093 Stock Forecast FAQ

What is HK:1093’s average 12-month price target, according to analysts?
Based on analyst ratings, CSPC Pharmaceutical Group Limited’s 12-month average price target is 11.28.
    What is HK:1093’s upside potential, based on the analysts’ average price target?
    CSPC Pharmaceutical Group Limited has 21.80% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CSPC Pharmaceutical Group Limited a Buy, Sell or Hold?
          CSPC Pharmaceutical Group Limited has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 4 hold ratings and 2 sell ratings.
            What is CSPC Pharmaceutical Group Limited’s share price target?
            The average share price target for CSPC Pharmaceutical Group Limited is 11.28. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$19.25 ,and the lowest forecast is HK$7.20. The average share price target represents 21.80% Increase from the current price of HK$9.26.
              What do analysts say about CSPC Pharmaceutical Group Limited?
              CSPC Pharmaceutical Group Limited’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of CSPC Pharmaceutical Group Limited?
                To buy shares of HK:1093, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.